Novel antibiotics against Staphylococcus aureus without detectable resistance by targeting proton motive force and...

Area of Science:

• Microbiology
• Infectious Diseases
• Drug Discovery

Background:

• Methicillin-resistant Staphylococcus aureus (MRSA) and its biofilms present significant health challenges, particularly in treating osteomyelitis.
• Existing treatments often fail, necessitating the development of novel antimicrobial agents.

Purpose of the Study:

• To identify and characterize novel small molecules with potent antimicrobial activity against MRSA.
• To investigate the mechanisms of action and in vivo efficacy of these compounds.

Main Methods:

• High-throughput screening and rational drug design.
• Transcriptomics, fluorescent probes, molecular dynamics, and surface plasmon resonance for mechanism studies.
• In vivo efficacy testing in abscess, peritonitis-sepsis, and periprosthetic joint infection models.

Main Results:

• Identification of C218-0546 and STK848198 with potent anti-MRSA activity, avoiding resistance.
• Demonstration of synergistic effects with conventional antibiotics.
• Elucidation of potential targets including proton motive force and FtsH.
• Successful in vivo efficacy in multiple infection models, including biofilm-related infections.

Conclusions:

• STK848198 and C218-0546 represent a novel class of antimicrobials with potential for treating MRSA infections.
• These compounds demonstrate efficacy against biofilms by targeting the quorum sensing system.
• The identified molecules show promising pharmacokinetic and toxicity profiles for further development.